Apogee Therapeutics, Inc. (NASDAQ:APGE) Receives Average Rating of “Buy” from Brokerages
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is […]
Apogee Therapeutics, Inc. (NASDAQ:APGE – Get Free Report) has earned an average rating of “Buy” from the five brokerages that are currently covering the stock, Marketbeat.com reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is […]
